MALVERN, PA — YPrime unveiled new research showing that artificial intelligence can dramatically reduce human error and accelerate global clinical trial startup, cutting eCOA localization review cycles by two-thirds and slashing migration errors by 74% in one of the industry’s most overlooked and error-prone processes.
The findings, presented at ISPOR 2025, examined how AI can transform eCOA text migration — the technical step where translated clinical assessments are imported into digital systems used in global trials. Using data from 15 studies in 11 languages, YPrime’s proprietary AI workflow not only reduced mistakes but introduced no new error types, a notable benchmark in digital quality assurance.
“Localization is one of the most critical — and least automated — steps in global trial readiness,” said Dr. Karl McEvoy, YPrime’s vice president of eCOA and patient technologies. He said AI trained on eCOA-specific structures eliminates the most error-prone tasks, giving reviewers cleaner material, faster approvals, and more inclusive language coverage.
YPrime’s analysis showed major gains: a 60% drop in error-containing screen reports, a 67% reduction in localization review time, and first-round proofreading approvals for half of languages tested — far above the industry norm. Faster approvals lead to earlier site activation and first-patient-in milestones, reducing overall trial delays and costs.
The company said the improvements have significant implications for global inclusion. When localization timelines tighten, rare or less common languages are often cut from trial protocols, excluding patients far beyond their home countries. By speeding up the workflow, AI helps sponsors preserve broader language coverage and ensure more equitable access to research.
YPrime continues to expand its AI-enabled eCOA platform, including advanced oversight tools, automated data-change forms, and connected-device integrations. The company is now moving toward predictive quality scoring, aiming to flag high-risk content before human review begins.
The company was recently named a Leader in Everest Group’s 2025 eCOA PEAK Matrix Assessment and recognized as a 2024 Trailblazer in Patient Engagement.
YPrime experts will discuss the study in a December 3 webinar. The full ISPOR poster is available at yprime.com.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.